Practical molecular diagnostics in neuropathology: Making a tough job a little easier

Seminars in Diagnostic Pathology

Volumn 27, Issue 2, 2010, Pages 105-113

  Horbinski, Craig ^a  

^a UNIVERSITY OF KENTUCKY   (United States)

Author keywords

1p19q; EGFR; IDH1; P16

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 2A; EPIDERMAL GROWTH FACTOR RECEPTOR; ISOCITRATE DEHYDROGENASE; PROTEIN P16; DNA; IDH1 PROTEIN, HUMAN; ISOCITRATE DEHYDROGENASE 2, HUMAN;

ADULT; AGED; ARTICLE; ASTROCYTOMA; BRAIN TUMOR; CHROMOSOME 19Q; CHROMOSOME 1P; CHROMOSOME DELETION; CLINICAL ARTICLE; DIAGNOSTIC ERROR; DIAGNOSTIC TEST; DIFFERENTIAL DIAGNOSIS; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GLIOBLASTOMA; GLIOMA; HETEROZYGOSITY LOSS; HUMAN; IMAGE ANALYSIS; IMAGE ENHANCEMENT; MALE; MEDICAL INFORMATION; MOLECULAR BIOLOGY; MUTATIONAL ANALYSIS; NEUROPATHOLOGY; NUCLEAR MAGNETIC RESONANCE IMAGING; OLIGODENDROGLIOMA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; STEREOTACTIC BIOPSY; BRAIN NEOPLASMS; CASE REPORT; CHROMOSOME 1; DNA SEQUENCE; GENE AMPLIFICATION; GENE DELETION; GENETICS; METABOLISM; MIDDLE AGED; MOLECULAR DIAGNOSIS; MUTATION; TUMOR SUPPRESSOR GENE;

ADULT; AGED; BRAIN NEOPLASMS; CHROMOSOME DELETION; CHROMOSOMES, HUMAN, PAIR 1; DNA, NEOPLASM; FEMALE; GENE AMPLIFICATION; GENE DELETION; GENES, P16; GLIOMA; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; ISOCITRATE DEHYDROGENASE; MALE; MIDDLE AGED; MOLECULAR DIAGNOSTIC TECHNIQUES; MUTATION; POLYMERASE CHAIN REACTION; RECEPTOR, EPIDERMAL GROWTH FACTOR; SEQUENCE ANALYSIS, DNA;

EID: 77955254003     PISSN: 07402570     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.semdp.2010.04.001     Document Type: Article

References (55)

1. Hegi M.E., Liu L., Herman J.G., et al. Correlation of O6-methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity. J Clin Oncol 2008, 26:4189-4199.
2. Yip S., Iafrate A.J., Louis D.N. Molecular diagnostic testing in malignant gliomas: A practical update on predictive markers. J Neuropathol Exp Neurol 2008, 67:1-15.
3. Louis D.N., Ohgaki H., Wiestler O.D., et al. WHO Classification of Tumors of the Central Nervous System 2007, IARC, Lyon, (eds). (ed 4).
4. Miller C.R., Dunham C.P., Scheithauer B.W. Significance of necrosis in grading of oligodendroglial neoplasms: A clinicopathologic and genetic study of newly diagnosed high-grade gliomas. J Clin Oncol 2006, 24:5419-5426.
5. Stupp R., Mason W.P., van den Bent M.J., et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005, 352:987-996.
6. Giannini C., Burger P.C., Berkey B.A., et al. Anaplastic oligodendroglial tumors: Refining the correlation among histopathology, 1p 19q deletion and clinical outcome in InterGroup Radiation Therapy Oncology Group Trial 9402. Brain Pathol 2008, 18:360-369.
7. Cairncross G., Berkey B., et al. Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: InterGroup Radiation Therapy Oncology Group Trial 9402. J Clin Oncol 2006, 24:2707-2714. Intergroup Radiation Therapy Oncology Group Trial 9402.
8. Jenkins R.B., Curran W., Scott C.B. Pilot evaluation of 1p and 19q deletions in anaplastic oligodendrogliomas collected by a national cooperative cancer treatment group. Am J Clin Oncol 2001, 24:506-508.
9. Smith J.S., Alderete B., Minn Y., et al. Localization of common deletion regions on 1p and 19q in human gliomas and their association with histological subtype. Oncogene 1999, 18:4144-4152.
10. Cairncross J.G., Ueki K., Zlatescu M.C., et al. Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst 1998, 90:1473-1479.
11. Canova C., Chevalier G., Remy S., et al. Epigenetic control of programmed cell death: Inhibition by 5-azacytidine of 1,25-dihydroxyvitamin D3-induced programmed cell death in C6.9 glioma cells. Mech Ageing Dev 1998, 101:153-166.
12. Griffin C.A., Burger P., Morsberger L., et al. Identification of der(1; 19) (q10; p10) in five oligodendrogliomas suggests mechanism of concurrent 1p and 19q loss. J Neuropathol Exp Neurol 2006, 65:988-994.
13. Jenkins R.B., Blair H., Ballman K.V., et al. A t(1;19)(q10;p10) mediates the combined deletions of 1p and 19q and predicts a better prognosis of patients with oligodendroglioma. Cancer Res 2006, 66:9852-9861.
14. Weller M., Berger H., Hartmann C., et al. Combined 1p/ 19q loss in oligodendroglial tumors: Predictive or prognostic biomarker?. Clin Cancer Res 2007, 13:6933-6937.
15. Barbashina V., Salazar P., Holland E.C., et al. Allelic losses at 1p36 and 19q13 in gliomas: Correlation with histologic classification, definition of a 150-kb minimal deleted region on 1p36, and evaluation of CAMTA1 as a candidate tumor suppressor gene. Clin Cancer Res 2005, 11:1119-1128.
16. Blesa D., Mollejo M., Ruano Y., et al. Novel genomic alterations and mechanisms associated with tumor progression in oligodendroglioma and mixed oligoastrocytoma. J Neuropathol Exp Neurol 2009, 68:274-285.
17. Ohgaki H., Kleihues P. Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas. J Neuropathol Exp Neurol 2005, 64:479-489.
18. Wick W., Hartmann C., Engel C., et al. NOA-04 Randomized Phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide. J Clin Oncol 2009, 27:5874-5880.
19. Eoli M., Bissola L., Bruzzone M.G., et al. Reclassification of oligoastrocytomas by loss of heterozygosity studies. Int J Cancer 2006, 119:84-90.
20. Horbinski C., Hamilton R.L., Nikiforov Y. Association of molecular alterations, including BRAF, with biology and outcome in pilocytic astrocytomas. Acta Neuropathol 2010, 119:641-649.
21. Lopez-Gines C., Gil-Benso R., Benito R., et al. The activation of ERK1/2 MAP kinases in glioblastoma pathobiology and its relationship with EGFR amplification. Neuropathology 2008, 28:507-515.
22. McLendon R.E., Turner K., Perkinson K. Second messenger systems in human gliomas. Arch Pathol Lab Med 2007, 131:1585-1590.
23. Mizoguchi M., Betensky R.A., Batchelor T.T., et al. Activation of STAT3, MAPK, and AKT in malignant astrocytic gliomas: Correlation with EGFR status, tumor grade, and survival. J Neuropathol Exp Neurol 2006, 65:1181-1188.
24. Gao C.F., Xie Q., Su Y.L., et al. Proliferation and invasion: Plasticity in tumor cells. Proc Natl Acad Sci U S A 2005, 102:10528-10533.
25. Berens M.E., Rief M.D., Shapiro J.R., et al. Proliferation and motility responses of primary and recurrent gliomas related to changes in epidermal growth factor receptor expression. J Neuro Oncol 1996, 27:11-22.
26. Guha A., Feldkamp M.M., Lau N., et al. Proliferation of human malignant astrocytomas is dependent on Ras activation. Oncogene 1997, 15:2755-2765.
27. Chakravarti A., Chakladar A., Delaney M.A., et al. The epidermal growth factor receptor pathway mediates resistance to sequential administration of radiation and chemotherapy in primary human glioblastoma cells in a RAS-dependent manner. Cancer Res 2002, 62:4307-4315.
28. Fuller C.E., Schmidt R.E., Roth K.A., et al. Clinical utility of fluorescence in situ hybridization (FISH) in morphologically ambiguous gliomas with hybrid oligodendroglial/astrocytic features. J Neuropathol Exp Neurol 2003, 62:1118-1128.
29. Dehais C., Laigle-Donadey F., Marie Y., et al. Prognostic stratification of patients with anaplastic gliomas according to genetic profile. Cancer 2006, 107:1891-1897.
30. Furnari F.B., Fenton T., Bachoo R.M., et al. Malignant astrocytic glioma: Genetics, biology, and paths to treatment. Genes Dev 2007, 21:2683-2710.
31. Korshunov A., Sycheva R., Golanov A. Molecular stratification of diagnostically challenging high-grade gliomas composed of small cells: The utility of fluorescence in situ hybridization. Clin Cancer Res 2004, 10:7820-7826.
32. Perry A., Aldape K.D., George D.H. Small cell astrocytoma: An aggressive variant that is clinicopathologically and genetically distinct from anaplastic oligodendroglioma. Cancer 2004, 101:2318-2326.
33. Kleihues P., Soylemezoglu F., Schauble B., et al. Histopathology, classification, and grading of gliomas. Glia 1995, 15:211-221.
34. Ohgaki H., Kleihues P. Genetic alterations and signaling pathways in the evolution of gliomas. Cancer Sci 2009, 100:2235-2241.
35. Parsons D.W., Jones S., Zhang X., et al. An integrated genomic analysis of human glioblastoma multiforme. Science 2008, 321:1807-1812.
36. Balss J., Meyer J., Mueller W., et al. Analysis of the IDH1 codon 132 mutation in brain tumors. Acta Neuropathol 2008, 116:597-602.
37. Bleeker F.E., Lamba S., Leenstra S., et al. IDH1 mutations at residue p.R132 (IDH1(R132)) occur frequently in high-grade gliomas but not in other solid tumors. Hum Mutat 2009, 30:7-11.
38. Yan H., Parsons D.W., Jin G., et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med 2009, 360:765-773.
39. Hartmann C., Meyer J., Balss J., et al. Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: A study of 1,010 diffuse gliomas. Acta Neuropathol 2009, 118:469-474.
40. Ichimura K., Pearson D.M., Kocialkowski S., et al. IDH1 mutations are present in the majority of common adult gliomas but rare in primary glioblastomas. Neuro Oncol 2009, 11:341-347.
41. Watanabe T., Nobusawa S., Kleihues P. IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas. Am J Pathol 2009, 174:1149-1153.
42. Park S.W., Chung N.G., Han J.Y., et al. Absence of IDH2 codon 172 mutation in common human cancers. Int J Cancer 2009, 125:2485-2486.
43. Gaal J., Burnichon N., Korpershoek E., et al. Isocitrate dehydrogenase mutations are rare in pheochromocytomas and paragangliomas. J Clin Endocrinol Metab 2009, 95:1274-1278.
44. Kang M.R., Kim M.S., Oh J.E., et al. Mutational analysis of IDH1 codon 132 in glioblastomas and other common cancers. Int J Cancer 2009, 125:353-355.
45. Mardis E.R., Ding L., Dooling D.J., et al. Recurring mutations found by sequencing an acute myeloid leukemia genome. N Engl J Med 2009, 361:1058-1066.
46. Dubbink H.J., Taal W., van Marion R., et al. IDH1 mutations in low-grade astrocytomas predict survival but not response to temozolomide. Neurology 2009, 73:1792-1795.
47. Weller M., Felsberg J., Hartmann C., et al. Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: A prospective translational study of the German Glioma Network. J Clin Oncol 2009, 27:5743-5750.
48. Sanson M., Marie Y., Paris S., et al. Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas. J Clin Oncol 2009, 27:4150-4154.
49. Nobusawa S., Watanabe T., Kleihues P. IDH1 mutations as molecular signature and predictive factor of secondary glioblastomas. Clin Cancer Res 2009, 15:6002-6007.
50. Horbinski C., Kofler J., Kelly L.M., et al. Diagnostic use of IDH1/2 mutation analysis in routine clinical testing of formalin-fixed, paraffin-embedded glioma tissues. J Neuropathol Exp Neurol 2009, 68:1319-1325.
51. Camelo-Piragua S., Jansen M., Ganguly A., et al. Mutant IDH1-specific immunohistochemistry distinguishes diffuse astrocytoma from astrocytosis. Acta Neuropathol 2010, 119:509-511.
52. Felsberg J., Wolter M., Seul H., et al. Rapid and sensitive assessment of the IDH1 and IDH2 mutation status in cerebral gliomas based on DNA pyrosequencing. Acta Neuropathol 2010, 119:501-507.
53. Capper D., Weissert S., Balss J., et al. Characterization of R132H mutation-specific IDH1 antibody binding in brain tumors. Brain Pathol 2010, 20:245-254.
54. Capper D., Zentgraf H., Balss J., et al. Monoclonal antibody specific for IDH1 R132H mutation. Acta Neuropathol 2009, 118:599-601.
55. Kato Y., Jin G., Kuan C.T., et al. A monoclonal antibody IMab-1 specifically recognizes IDH1(R132H), the most common glioma-derived mutation. Biochem Biophys Res Commun 2009, 390:547-551.